ASSERTIO THERAPEUTICS, INC. Net Change in Cash
ASSERTIO THERAPEUTICS, INC. reported Net Change in Cash of $63.87 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2020-05-11
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $63.87M.
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-03-31 was -$1.26M.
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2018-03-31 was -$25.19M.
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$68.84M.
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2018 was -$15.94M, a 273.68% decline from fiscal 2017.
- ASSERTIO THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2017 was $9.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2020-03-31 | $63.87M 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | -$68.84M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | -$56.77M 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | -$42.60M 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | -$1.26M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$15.94M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | -$4.98M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | -$69.65M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | -$25.19M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $9.18M 10-K · filed 2020-03-10 |